The Food and Drug Administration has granted Fast Track designation to APD418 (Arena Pharmaceuticals) for the treatment of decompensated heart failure.
APD418 is a first-in-class β3 adrenergic receptor selective antagonist and cardiac myotrope that is expected to improve cardiac contractility with little effect on heart rate, blood pressure and myocardial oxygen consumption, thereby avoiding potential adverse events often associated with current inotropic therapies. A phase 1 study is currently ongoing with data expected later this year.
“With approximately 10 million [decompensated heart failure] patient hospital visits expected in the US by 2025 and few viable treatment options, we believe that APD418 has the potential to make a significant impact for these patients,” stated Chris Cabell, MD, MHS, FACC, Arena’s Senior Vice President and Chief Medical Officer. “We are pleased with the Fast Track designation and look forward to advancing this program as part of our cardiovascular focus.”
For more information visit arenapharm.com.
This article originally appeared on MPR